中文
中文
为了病患而驱动的创新
Patient-first cell therapy innovation

Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma.
  • 0
Jia Q., Qin D., He F., Xie Q., Ying Z., Zhang Y., Song Y., Cheng J.N., Zuo X., Xu L., Fang H., Hu C., Peng L., Jin T., Shi Z., Alexander P.B., Wang Y., Liu Y., Han W., Zhu J., Wang P.*, Li Q.-J.*, Zhu B.* (2021) Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma. Theranostics 11(10):4699-4709. (*: Corresponding authors, PMCID: PMC7978305)


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7978305/


Copyright © 2019 天科雅生物医药科技有限公司

粤公网安备 44011502000528号

粤ICP备20056630号 Powered by vancheer
关于天科雅
研究与发展
产品及临床
新闻与媒体
招贤纳士

Copyright © 2019 天科雅生物医药科技有限公司

粤公网安备 44011502000528号

粤ICP备20056630号 Powered by vancheer